What is the recommended initial treatment and management plan for glaucoma?

Initial Treatment for Glaucoma

For newly diagnosed primary open-angle glaucoma (POAG), start with a prostaglandin analog (latanoprost, bimatoprost, or travoprost) as first-line medical therapy, with selective laser trabeculoplasty (SLT) as an equally effective alternative initial option. 1, 2

First-Line Medical Therapy

Prostaglandin analogs are the preferred initial medication because they provide the most effective IOP reduction (4.37-5.61 mmHg), require only once-daily dosing, and have the best tolerability profile 3. Among prostaglandins:

• Bimatoprost achieves the greatest IOP reduction (5.61 mmHg at 3 months)
• Latanoprost reduces IOP by 4.85 mmHg
• Travoprost reduces IOP by 4.83 mmHg

The differences between these agents are small and likely not clinically meaningful, so selection can be based on cost, availability, and patient-specific factors 3.

Alternative First-Line Options

If prostaglandin analogs are contraindicated or not tolerated, the hierarchy of alternatives based on efficacy is 3:

1. Beta-blockers (levobunolol 4.51 mmHg, timolol 3.70 mmHg) - avoid in patients with asthma, COPD, bradycardia, or heart block
2. Alpha-2 agonists (brimonidine 3.59 mmHg) - contraindicated in infants and nursing mothers due to CNS depression risk 4
3. Topical carbonic anhydrase inhibitors (dorzolamide 2.49 mmHg, brinzolamide 2.42 mmHg)

Laser Trabeculoplasty as Initial Treatment

SLT can be offered as initial therapy instead of medications, particularly for patients with adherence concerns, medication intolerance, or patient preference 4. The evidence supporting this approach:

• The Glaucoma Laser Trial demonstrated that initial laser trabeculoplasty lowered IOP more than timolol (9 mmHg vs 7 mmHg) and was equally effective in preserving visual fields over 5.5 years 4
• SLT provides comparable IOP reduction to prostaglandin analogs when 360 degrees of trabecular meshwork is treated 4
• SLT has a favorable safety profile with only mild anterior chamber inflammation 4

Critical perioperative management for laser trabeculoplasty 4:

• Check IOP immediately before and 30 minutes to 2 hours after the procedure
• Use prophylactic brimonidine or apraclonidine to prevent IOP spikes (occur in 4.5-27% of cases)
• Treat 180 degrees rather than 360 degrees to reduce postoperative IOP elevation
• Follow-up within 6 weeks

Target IOP Setting

Set initial target IOP at 20% below the mean of several baseline measurements 1, 2. This is based on the Ocular Hypertension Treatment Study criteria. However, if baseline IOP is markedly elevated, a 20% reduction may be insufficient.

Reassess and lower the target if:

• Visual field or optic nerve deterioration occurs despite treatment
• The patient has advanced disease at presentation
• There are additional risk factors (family history, thin central corneal thickness, older age)

Escalation Strategy

If target IOP is not achieved with monotherapy 1:

1. Add a second medication from a different class (combination therapy may reduce adherence, so consider fixed-combination products)
2. Switch to alternative monotherapy if the first agent is ineffective
3. Add laser trabeculoplasty if not already performed
4. Proceed to incisional surgery (trabeculectomy or tube shunt) when medical and laser therapy fail

Surgical Considerations

Trabeculectomy is indicated when medications and laser therapy are insufficient, but can be considered as initial therapy in selected cases 4. Key evidence:

• The Moorfields Primary Treatment Trial showed trabeculectomy achieved 60% IOP reduction versus 49% with medical therapy and 38% with laser, with better visual field preservation 4
• The Early Manifest Glaucoma Trial demonstrated that lowering IOP by 25% with medical therapy and trabeculoplasty slowed progression 4, 5
• Use of antifibrotic agents (mitomycin-C or 5-fluorouracil) reduces surgical failure rates but increases risks of hypotony, bleb leak, and late infection 4

Critical Pitfalls to Avoid

Medication adherence is poor - nearly 45% of patients take fewer than 75% of prescribed doses even with once-daily medications 1. Address this by:

• Linking drop administration to daily activities
• Providing repeated instruction on proper instillation technique
• Considering SLT for patients with adherence concerns
• Using fixed-combination products when multiple medications are needed

Avoid brimonidine in nursing mothers - it crosses into breast milk and can cause life-threatening apnea in infants 4.

Monitor for IOP spikes after laser trabeculoplasty, especially in heavily pigmented trabecular meshwork 4.

Beta-blockers dosed at night have limited efficacy and may contribute to visual field progression through nocturnal blood pressure reduction 2.